MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    Disease severity is not predictive of the dose required for apomorphine sublingual film (APL-130277) to convert a patient with Parkinson’s disease(PD) from OFF to fully ON: Preliminary Results from a Phase III Study

    H. Fernandez, S. Isaacson, A. Espay, R. Pahwa, D. Truong, E. Pappert, P. Gardzinski, B. Dzyngel, A. Agro, R. Hauser (Cleveland, OH, USA)

    Objective: To determine if baseline disease severity could be correlated to the effective dose of APL-130277 that was required to turn a patient with PD…
  • 2017 International Congress

    Pharmacokinetic profile of continuous levodopa/carbidopa delivery when administered subcutaneously (ND0612) versus duodenal infusion (levodopa/carbidopa intestinal gel)

    L. Adar, T. Rachmilewitz Minei, Y. Cohen, S. Oren (Rehovot, Israel)

    Objective: To compare levodopa PK, derived from ND0612 (a proprietary liquid levodopa/carbidopa formulation designed for subcutaneous (SC) administration) with Levodopa/Carbidopa Intestinal Gel (LCIG). Background: While…
  • 2017 International Congress

    Does the side of onset affect motor and non-motor symptoms in Parkinson’s disease?

    J. Silva, A. D'Abreu (Campinas, Brazil)

    Objective: To assess the association between motor and non-motor symptoms of Parkinson’s Disease (PD) and side of onset considering hand dominance. Background: PD motor symptoms…
  • 2017 International Congress

    Effect of levodopa-carbidopa intestinal gel on dyskinesia: Design of an open-label, randomized multicenter 12-week study in advanced Parkinson’s disease patients

    A. Antonini, W. Poewe, D. Standaert, C. Zadikoff, S. Dubow, L. Bergmann, A. Yegin, C. Hall, W. Robieson, V. Felipe, L. Barbato (Venice, Italy)

    Objective: To examine the effect of levodopa-carbidopa intestinal gel (LCIG, designated carbidopa-levodopa enteral suspension in the US) treatment relative to that of optimized medical treatment…
  • 2017 International Congress

    Subthalamic Nucleus Deep Brain Stimulation in Early Stage Parkinson’s Disease Reduces the Risk of Polypharmacy: Five-Year Analysis

    M. Hacker, M. Turchan, A. Currie, L. Heusinkveld, S. Millan, T. Davis, F. Phibbs, P. Hedera, P. Konrad, D. Charles (Nashville, TN, USA)

    Objective: To compare the proportion of subjects on polypharmacy after five years in the deep brain stimulation (DBS) in early stage Parkinson’s disease (PD) pilot…
  • 2017 International Congress

    Outcomes of a Prospective, Multicenter International Registry of Deep Brain Stimulation for Parkinson’s Disease

    G. Deuschl, R. Jain, H. Scholtes, K. Steinke, A. Wang, A. Kühn, L. Timmermann, M. Pötter-Nerger, P. Eldridge, J. Volkmann, J. Fitzgerald, A. Schnitzler, H. Mehdorn, J. Vesper (Kiel, Germany)

    Objective: To investigate the effectiveness and safety-related real-world outcomes of a multiple-source, constant current Deep Brain Stimulation (DBS) System in the treatment of levodopa-responsive Parkinson’s…
  • 2017 International Congress

    Real World Clinical Outcomes Using a Novel Directional Lead from a Multicenter Registry of DBS for Parkinson’s disease

    G. Deuschl, R. Jain, H. Scholtes, K. Steinke, A. Wang, M. Pötter-Nerger, L. Timmermann, J. Volkmann, A. Kühn, P. Eldridge, J. Fitzgerald, H. Mehdorn, J. Vesper (Kiel, Germany)

    Objective: To evaluate clinical outcomes in subjects implanted with a Directional Lead for use in the treatment of levodopa-responsive Parkinson’s disease (PD) as part of…
  • 2017 International Congress

    INTREPID Trial: A Prospective, Double blinded, Multi-center Randomized Controlled Trial Evaluating Deep Brain Stimulation with a New Multiple-Source, Constant-Current Rechargeable System in Parkinson’s Disease

    J. Vitek, R. Jain, P. Starr (Minneapolis, MN, USA)

    Objective: The objective of the INTREPID clinical trial is to assess the improvement in motor function and quality of life in patients with advanced, levodopa-responsive…
  • 2017 International Congress

    Wearing Off Frequency in Different Hoehn-Yahr Stages in Parkinson’s Disease

    H. Cotur Levent, E. Bayram, M. Akbostanci (Ankara, Turkey)

    Objective: To determine wearing off frequency in different stages of Parkinson’s disease (PD). Background: Levodopa is the gold standard in the symptomatic treatment of PD. The…
  • 2017 International Congress

    Ambulatory movement measurement in evaluating deep brain stimulation effect in patients with advanced Parkinson’s disease

    M. Koivu, F. Scheperjans, E. Pekkonen (Helsinki, Finland)

    Objective: To assess  the  use of the Parkinson's  Kinetigraph™ (PKG™) in evaluating the effect of  deep brain stimulation (DBS)  in patients with advanced Parkinson's disease (PD). Background: Assessment of the effect of  DBS on bradykinesia…
  • « Previous Page
  • 1
  • …
  • 1322
  • 1323
  • 1324
  • 1325
  • 1326
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley